Athens (Greece), 23 January 2017
Probi’s patented, clinically-documented probiotic strains will complement BioAxess’s current OTC portfolio with probiotics for addressing Irritable Bowel Syndrome.
BioAxess was established in 2010 by a number of former multinational managers from pharmaceutical companies in Greece. They already have a number of well-known international brands in their portfolio. BioAxess now establishes a new business unit to focus on food and dietary supplements, with special emphasis on medical marketing and probiotics. Read More